Tempest Therapeutics Net Worth
Tempest Therapeutics Net Worth Breakdown | TPST |
Tempest Therapeutics Net Worth Analysis
Tempest Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tempest Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tempest Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tempest Therapeutics' net worth analysis. One common approach is to calculate Tempest Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tempest Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tempest Therapeutics' net worth. This approach calculates the present value of Tempest Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tempest Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tempest Therapeutics' net worth. This involves comparing Tempest Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tempest Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Tempest Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tempest Therapeutics' net worth research are outlined below:
| Tempest Therapeutics has some characteristics of a very speculative penny stock | |
| Tempest Therapeutics had very high historical volatility over the last 90 days | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (29.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (27.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma |
Tempest Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tempest Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tempest Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Tempest Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tempest Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tempest Therapeutics backward and forwards among themselves. Tempest Therapeutics' institutional investor refers to the entity that pools money to purchase Tempest Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-09-30 | 45.3 K | Bank Of America Corp | 2024-09-30 | 43.2 K | State Street Corp | 2024-09-30 | 41.5 K | Empower Advisory Group Llc | 2024-09-30 | 35 K | Tocqueville Asset Management L.p. | 2024-09-30 | 32.8 K | Advisor Group Holdings, Inc. | 2024-09-30 | 25.4 K | Boothbay Fund Management, Llc | 2024-09-30 | 24.6 K | Xtx Topco Ltd | 2024-09-30 | 24 K | Two Sigma Investments Llc | 2024-09-30 | 22.9 K | Blackrock Inc | 2024-09-30 | 551.6 K | Altium Capital Management, Lp | 2024-09-30 | 545 K |
Follow Tempest Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.24 M.Market Cap |
|
Project Tempest Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (1.27) | (1.33) |
When accessing Tempest Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tempest Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tempest Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tempest Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tempest Therapeutics. Check Tempest Therapeutics' Beneish M Score to see the likelihood of Tempest Therapeutics' management manipulating its earnings.
Evaluate Tempest Therapeutics' management efficiency
Tempest Therapeutics has return on total asset (ROA) of (0.5428) % which means that it has lost $0.5428 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8926) %, meaning that it created substantial loss on money invested by shareholders. Tempest Therapeutics' management efficiency ratios could be used to measure how well Tempest Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2025. Return On Capital Employed is likely to drop to -0.83 in 2025. Liabilities And Stockholders Equity is likely to gain to about 70.9 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.00 | 1.90 | |
| Tangible Book Value Per Share | 2.00 | 1.90 | |
| Enterprise Value Over EBITDA | (1.54) | (1.62) | |
| Price Book Value Ratio | 2.91 | 3.14 | |
| Enterprise Value Multiple | (1.54) | (1.62) | |
| Price Fair Value | 2.91 | 3.14 | |
| Enterprise Value | 56.7 M | 44.6 M |
Leadership at Tempest Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tempest Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tempest Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tempest Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tempest Therapeutics time-series forecasting models is one of many Tempest Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tempest Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Tempest Therapeutics Earnings per Share Projection vs Actual
Tempest Therapeutics Corporate Management
| Nicholas Maestas | VP Secretary | Profile | |
| Dr Dubensky | Pres Director | Profile | |
| Justin Trojanowski | Treasurer Controller | Profile | |
| RAC Sakai | Head Quality | Profile | |
| Samuel MD | Executive Officer | Profile | |
| Petpiboon Prasit | Acting Director | Profile | |
| Anne Moon | Project Leadership | Profile |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.